4.7 Article

Delivery of Evidence-Based Treatment for Multiple Anxiety Disorders in Primary Care A Randomized Controlled Trial

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 303, 期 19, 页码 1921-1928

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.608

关键词

-

资金

  1. National Institute of Mental Health [U01 MH057858, K24 MH065324, U01 MH058915, U01 MH070022, U01 MH070018, U01MH057835, K24 MH64122]
  2. National Institutes of Health
  3. US Department of Defense
  4. Eli Lilly
  5. GlaxoSmithKline
  6. Hoffmann-La Roche
  7. US Veterans Affairs

向作者/读者索取更多资源

Context Improving the quality of mental health care requires moving clinical interventions from controlled research settings into real-world practice settings. Although such advances have been made for depression, little work has been performed for anxiety disorders. Objective To determine whether a flexible treatment-delivery model for multiple primary care anxiety disorders (panic, generalized anxiety, social anxiety, and post-traumatic stress disorders) would be better than usual care (UC). Design, Setting, and Patients A randomized controlled effectiveness trial of Coordinated Anxiety Learning and Management(CALM) compared with UC in 17 primary care clinics in 4 US cities. Between June 2006 and April 2008, 1004 patients with anxiety disorders (with or with out major depression), aged 18 to 75 years, English-or Spanish-speaking, were enrolled and subsequently received treatment for 3 to 12 months. Blinded follow-up assessments at 6, 12, and 18 months after baseline were completed in October 2009. Intervention CALM allowed choice of cognitive behavioral therapy (CBT), medication, or both; included real-time Web-based outcomes monitoring to optimize treatment decisions; and a computer-assisted program to optimize delivery of CBT by nonexpert care managers who also assisted primary care clinicians in promoting adherence and optimizing medications. Main Outcome Measures Twelve-item Brief Symptom Inventory (BSI-12) anxiety and somatic symptoms score. Secondary outcomes included proportion of responders(>= 50% reduction from pretreatment BSI-12 score) and remitters (total BSI-12 score <6). Results A significantly greater improvement for CALM vs UC in global anxiety symptoms was found (BSI-12 group mean differences of -2.49 [95% confidence interval {CI}, -3.59 to -1.40], -2.63 [95% CI, -3.73 to -1.54], and -1.63 [95% CI, -2.73 to -0.53] at 6, 12, and 18 months, respectively). At 12 months, response and remission rates (CALM vs UC) were 63.66% (95% CI, 58.95%-68.37%) vs 44.68% (95% CI, 39.76%-49.59%), and 51.49% (95% CI, 46.60%-56.38%) vs 33.28% (95% CI, 28.62%-37.93%), with a number needed to treat of 5.27 (95% CI, 4.18-7.13) for response and 5.50 (95% CI, 4.32-7.55) for remission. Conclusion For patients with anxiety disorders treated in primary care clinics, CALM compared with UC resulted in greater improvement in anxiety symptoms, depression symptoms, functional disability, and quality of care during 18 months of follow-up.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据